U.S. Clinical Trial Packaging Market (2025 - 2030)

U.S. Clinical Trial Packaging Market Summary

The U.S. clinical trial packaging market size was estimated at USD 915.9 million in 2024 and is projected to reach USD 1,611.4 million by 2030, growing at a CAGR of 9.9% from 2025 to 2030. The growth is driven by the increasing number of clinical trials, particularly for novel drugs and therapies, including biologics and gene therapies.

The rising prevalence of chronic diseases necessitates continuous research and development in the pharmaceutical and biotechnology sectors, leading to a higher demand for specialized packaging solutions to ensure drug stability, safety, and integrity throughout the trial phases. Increasing regulatory scrutiny and the complexity of trial protocols necessitate secure and adaptive packaging formats. The growth of the U.S. clinical trial packaging industry is primarily driven by the rising number of clinical trials, spurred by growing investments in pharmaceutical R&D and the surge in novel drug development.

Innovation is a cornerstone of the U.S. clinical trial packaging industry, continuously driven by the need for enhanced drug stability, patient compliance, and supply chain efficiency. Companies invest in smart packaging technologies, such as RFID and temperature monitoring devices, to provide real-time data on product conditions and ensure integrity throughout cold chain logistics.

Material Insights

The plastic material segment held the largest revenue share of 53.8% in 2024, largely due to its versatility, cost-effectiveness, and ability to be customized for various drug forms, including solid doses, liquids, and semi-solids. It is commonly used for bottles, pouches, and vials. The increasing need for sterile, single-use packaging solutions in trials and rising clinical research activities further enhances plastic's dominance.

The metal segment is expected to grow at the fastest CAGR of 10.8% over the forecast period. This growth is attributed to the superior barrier properties of metal, offering robust protection against light, moisture, and oxygen, which is critical for highly sensitive or high-value drug products.Metal packaging provides exceptional durability and tamper-evident features, crucial for maintaining product integrity and security throughout the complex clinical trial supply chain.

Product Insights

The vials & ampoules segment held the largest revenue share in 2024 and is expected to grow at the fastest CAGR over the forecast period. The growth is due to their versatility in holding lyophilized, liquid and powder-based drugs. Vials offer reusability and resealing features, while ampoules offer a tamper-proof single-use solution. Growth in parenteral drug development and temperature-sensitive biologics also fuels the need for durable, inert packaging such as vials and ampoules.

The bags and pouches segment is expected to grow at a significant CAGR over the forecast period. requirements make them an increasingly preferred choice among clinical research organizations and sponsors seeking compliance and logistical efficiency.

End Use Insights

The research laboratories segment dominated the market in 2024. Research laboratories are key stakeholders in early-stage drug development and are responsible for preclinical and clinical testing. These laboratories require specialized clinical trial packaging solutions to ensure sample integrity, compliance with regulatory standards, and efficient identification during complex trials.

The clinical research organizations segment is expected to experience the fastest CAGR over the forecast period.This rapid growth is fueled by the increasing trend of pharmaceutical and biotechnology companies outsourcing their clinical trial management, including specialized packaging, labeling, and distribution services, to CROs. They offer expertise and infrastructure to manage complex supply chains, cold chain logistics, and regulatory compliance for clinical trial materials.

Key U.S. Clinical Trial Packaging Company Insights

Some of the key players operating in the market include Catalent, Inc., PCI Pharma Services, Xerimis, and others.

• Catalent provides advanced delivery technologies and development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. It offers comprehensive clinical supply services for clinical trials, including secondary packaging and clinical labeling, often performed in temperature-controlled environments.

Recent Developments

• In September 2024, PCI Pharma Services announced a USD 365 million investment in European Union and the U.S. facilities for clinical and commercial scale supply of advanced drug device combination and drug delivery products.

U.S. Clinical Trial Packaging Market